Can HBOT Help With Migraines? What the Evidence Says

Quick Answer

Hyperbaric oxygen therapy shows evidence of helping with acute migraine attacks — a 2015 Cochrane systematic review found HBOT provided short-term relief when administered during an active migraine, typically in an emergency or clinical setting at pressures around 2.0 ATA. Evidence for using HBOT to prevent future migraines is much weaker and considered insufficient. These are two different clinical questions with two different answers, and most online content conflates them.

Two Different Questions, Two Different Answers

Migraine-related HBOT research splits cleanly into two categories that get confused constantly in casual discussion:

This has actual supporting evidence — the strongest evidence category in this article.

This has very limited evidence — mostly small studies and case reports, not strong enough to draw conclusions.

Understanding this distinction matters, because “HBOT helps migraines” without specifying which question you’re asking is close to meaningless.

What the Cochrane Review Found

Review Detail	Finding
Acute attack treatment	Some evidence that hyperbaric oxygen relieves migraine symptoms when given during an attack
Migraine prevention	Insufficient evidence to draw conclusions on regular/prophylactic use
Cluster headache	Similarly, some support for acute attack relief; insufficient data for prevention
Pressure typically used	Around 2.0 ATA in the acute-treatment studies reviewed

The acute-treatment finding lines up with a plausible mechanism: migraines are associated with changes in cerebral blood flow and vessel dilation, and high-pressure oxygen has vasoconstrictive effects that may interrupt the attack in progress. This is actually similar to why supplemental oxygen (at normal pressure) is a recognized acute treatment for cluster headaches specifically.

Why This Matters for Anyone Considering HBOT for Migraines

If your interest is stopping migraines already in progress, the research points to clinical-pressure oxygen delivered in a medical setting during the attack — not a routine you’d build around a home wellness chamber, since migraines are unpredictable and the studied intervention happens at the time of the attack itself, typically in an ER or specialized clinic.

If your interest is preventing migraines from happening — which is what most people actually want, since chronic migraine sufferers are looking for a way to reduce frequency, not just treat individual attacks — the evidence for HBOT simply isn’t there yet. Established migraine prevention strategies (identifying triggers, certain medications, CGRP inhibitors, lifestyle factors like sleep and hydration) have far more research behind them.

Factor	Acute Attack Treatment (Studied)	Migraine Prevention (Not Well Studied)
Setting	Emergency/clinical, during attack	N/A — not established
Pressure	~2.0 ATA	N/A
Recommended approach	Discuss with a neurologist for acute options	Standard migraine prevention protocols

Where Mild HBOT Fits — And Where It Doesn’t

We’re not going to claim mild hyperbaric chambers treat active migraine attacks — that’s not how the acute-treatment research works, and a home wellness chamber isn’t positioned as an emergency intervention. What we can say is that some migraine sufferers report that stress, poor sleep, and tension are triggers or amplifiers of their migraine frequency — and general relaxation and oxygen-enriched rest, independent of any specific migraine claim, is sometimes incorporated into a broader wellness routine aimed at managing those trigger factors.

The AURA One offers a quiet, dimly-lit, low-stimulation environment — which matters for anyone sensitive to light and noise, a common experience for migraine sufferers even between attacks. This is general wellness positioning, not a claim that the chamber prevents or treats migraines.

FAQ

There’s some supporting evidence from a Cochrane systematic review showing hyperbaric oxygen can relieve symptoms during an active migraine attack, typically administered in a clinical setting at around 2.0 ATA.

The evidence here is insufficient. Unlike acute attack treatment, migraine prevention has not been well studied with HBOT, and no strong recommendation can be made.

No. Migraine is not among the FDA’s approved HBOT indications, though the acute-treatment evidence has been reviewed favorably by Cochrane researchers as a topic worth further study.

Studies reviewed by Cochrane generally used pressures around 2.0 ATA, delivered in clinical or emergency settings during an active attack — different from the 1.1–1.7 atm range of mild home hyperbaric chambers.

There’s no strong evidence for HBOT as migraine prevention at any pressure level, including clinical pressure. A mild chamber may support general relaxation as part of trigger management, but shouldn’t be relied on as a preventive migraine treatment.

This article is for educational purposes only and is not medical advice. Migraine is not an FDA-approved indication for HBOT. Evidence supports possible benefit for acute attack treatment in a clinical setting; evidence for prevention is insufficient. Anyone with frequent or severe migraines should consult a neurologist. HyperbaricO2Care manufactures mild hyperbaric chambers (1.1–1.7 atm) intended for general wellness use and does not claim its equipment treats or prevents migraines. Reference: Bennett et al., “Normobaric and hyperbaric oxygen therapy for migraine and cluster headache,” Cochrane Database of Systematic Reviews (2015).